Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Eli Lilly reports before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Lilly's post-earnings price behavior shows significant volatility with an average absolute Day 0 move of 8.03% and an average Day 0 range of 6.44%. The most dramatic reactions came in February 2026 (10.33% gain on Day 0, followed by a 7.79% decline on Day +1) and in the two May and August 2025 reports, which both saw double-digit Day 0 declines of 11.66% and 14.14% respectively despite the company beating estimates.

The Day +1 follow-through averages 3.06% with a 3.93% range, suggesting that initial reactions often moderate but meaningful secondary moves are common. Recent quarters show more controlled reactions — the August 2026 report produced a 4.86% Day 0 gain and 1.89% Day +1 gain, while April 2026 saw a 9.80% Day 0 surge followed by 3.57% Day +1 continuation. This pattern indicates that when Lilly delivers strong results with positive guidance, the stock can sustain multi-day rallies, but disappointments or guidance concerns can trigger sharp reversals even after beats.

Part 2.2: Options Market Expected Move

The options market is pricing a 5.22% expected move ($67.40) for the October 30 weekly expiration, which is substantially below the stock's 8.03% average absolute Day 0 move and even below the 6.44% average Day 0 range. This suggests options traders may be underpricing potential volatility, particularly given the recent pattern of large post-earnings swings and the heightened focus on margin sustainability at current valuation levels.

Part 3: What Analysts Are Saying

Analysts maintain overwhelmingly bullish sentiment on Eli Lilly with an average recommendation of 4.69 out of 5.00, reflecting strong conviction in the stock's long-term prospects. The consensus includes 23 Strong Buy ratings, 3 Moderate Buys, and 3 Hold ratings, with zero sell recommendations. This rating profile has remained unchanged over the past month, indicating stable analyst confidence despite the stock's recent rally to 52-week highs.

The average price target of $1,363.11 implies 5.8% upside from the current price of $1,288.30, with a wide range spanning from a low target of $915.00 to a high of $1,600.00. The $685 spread between high and low targets reflects divergent views on how successfully Lilly can navigate the pricing-versus-volume trade-off and whether its margin expansion story can continue. The mean target sitting only modestly above current levels suggests the recent rally has largely captured near-term upside, placing greater emphasis on this earnings report to either validate the premium valuation or trigger a reassessment.

The unchanged sentiment trend over the past month is notable given the stock's 8.74% gain during that period and the positive retatrutide trial data announced October 28. This stability suggests analysts were already positioned for good news and are now waiting for the October 29 report to confirm that operational execution — particularly margin performance and guidance — can support the elevated valuation. With the stock trading at 33x forward earnings and consensus estimates calling for EPS to nearly double from 2025 to 2027, analysts need this report to demonstrate that the margin expansion underpinning those projections remains on track.

Part 4: Technical Picture

The Barchart Technical Opinion shows maximum bullish conviction with a 100% Buy signal currently, up from 100% Buy last week and strengthening significantly from 72% Buy a month ago. This progression reflects strong technical momentum as the stock has rallied to new 52-week highs heading into earnings.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal indicates powerful near-term momentum supporting the rally into earnings
• Medium-term (100% Buy): Strongest possible reading confirms the uptrend is well-established across intermediate timeframes
• Long-term (100% Buy): Maximum bullish signal reflects sustained strength in the longer-term trend structure

Strong Strongest trend characteristics indicate the stock is in its most powerful technical configuration, with momentum aligned across all timeframes as it approaches the earnings release.

The stock closed at $1,288.30, trading below all major moving averages including the 5-day ($1,285.90), 10-day ($1,273.29), 20-day ($1,221.08), 50-day ($1,191.81), 100-day ($1,182.20), and 200-day ($1,088.04). This positioning above all key moving averages demonstrates a clean uptrend structure with no overhead resistance from prior consolidation levels.

The technical setup heading into earnings is exceptionally supportive, with the stock at 52-week highs, maximum buy signals across all timeframes, and a clean trend structure above all moving averages. The 18.4% cushion above the 200-day moving average provides substantial support, while the progression of moving averages in proper ascending order (5-day > 10-day > 20-day > 50-day > 100-day > 200-day) confirms trend health. However, this strength also means the stock has limited room for disappointment — any margin concerns or guidance that falls short of elevated expectations could trigger profit-taking from an extended technical position. The combination of maximum bullish signals and proximity to all-time highs creates an asymmetric risk profile where meeting expectations may not be enough to drive further gains, while any shortfall could produce an outsized reaction.